News|Articles|June 19, 2020

GSK Consumer Healthcare Recalls Children’s Cough Medicine

The products are being recalled because of missing graduation marks on the dosing cups

GSK Consumer Healthcare announced on June 18, 2020 it is voluntarily recalling two lots of Children's Robitussin Honey Cough and Chest Congestion DM and one lot of Children's Dimetapp Cold and Cough because of incorrect dosing cups. The cups for Children's Robitussin Honey product are missing the 5 mL and 10 mL graduations; the dosing cups for the Children's Dimetapp product are missing the 10 mL graduation; and the dosing cups included with both products only have the 20 mL graduation.

According to the company, there is a potential risk of accidental overdose if the discrepancies between the dose instructions and the graduations on the cups are not noticed before the product is administered. An overdose may cause impaired coordination, severe dizziness, slow heart rate, psychotic behavior, seizure, and a variety of other symptoms.

The recalled lots were distributed nationwide between Feb. 5, 2020 and June 3, 2020. The affected lots include: Children's Robitussin Honey Cough and Chest Congestion DM (4oz), NDC 0031-8760-12, Lots: 02177 (Exp. Jan. 2022) and 02178 (Exp. Jan. 2022); and Children's Dimetapp Cold and Cough (8oz), NDC 0031-2234-19, Lot: CL8292 (Exp. Sep. 2021). The company has not received any reports of adverse events related to the recalled lots. Adverse events may be reported to FDA through the agency’s MedWatch program.

Source: FDA


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.